Xiamen Amoytop Biotech Income Statement

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Operating Revenue	3,334	2,809	2,093	1,517	1,123	789.39
Other Revenue	7.75	7.75	7.74	10	9.51	4.54
Revenue	3,342	2,817	2,100	1,527	1,132	793.93
Revenue Growth (YoY)	28.78%	34.13%	37.55%	34.86%	42.61%	8.81%
Cost of Revenue	239.07	184.47	140.2	171.01	126.99	85.65
Gross Profit	3,103	2,633	1,960	1,356	1,005	708.29
Selling, General & Admin	1,672	1,393	1,060	841.02	700.65	503.55
Research & Development	378.02	292.02	228.52	148.58	79.74	74.23
Other Operating Expenses	11.43	13.3	10.95	7.64	5.55	3.83
Operating Expenses	2,065	1,702	1,300	995.83	783.6	581.42
Operating Income	1,038	930.33	659.88	360.06	221.64	126.86
Interest Expense	-0.86	-0.45	-0.51	-0.62	-1.07	-2.46
Interest & Investment Income	8.39	6.99	10.17	8.09	7.84	3.67
Currency Exchange Gain (Loss)	-0.12	-0.12	-1.03	0.48	-0.47	-0.95
Other Non Operating Income (Expenses)	26.98	-0.09	-0.39	-0.25	-0.24	0.39
EBT Excluding Unusual Items	1,073	936.67	668.13	367.77	227.69	127.51
Gain (Loss) on Sale of Investments	0.66	0.88	2.65	0.4	1.8	3.96
Gain (Loss) on Sale of Assets	-0.29	-0.03	-0.87	0.03	-1.8	-1.13
Asset Writedown	-	-	-12.76	-	-	-
Other Unusual Items	-56.66	-6.5	-16.49	-12.27	-12.4	8.73
Pretax Income	1,016	931.03	640.65	355.93	215.29	139.07
Income Tax Expense	76.7	103.42	85.21	68.91	34.09	22.5
Net Income	939.58	827.6	555.45	287.02	181.2	116.57
Net Income to Common	939.58	827.6	555.45	287.02	181.2	116.57
Net Income Growth	26.85%	49.00%	93.52%	58.40%	55.44%	81.31%
Shares Outstanding (Basic)	407	408	405	404	403	402
Shares Outstanding (Diluted)	407	408	405	404	403	402
Shares Change (YoY)	-0.07%	0.56%	0.29%	0.39%	0.18%	12.54%
EPS (Basic)	2.31	2.03	1.37	0.71	0.45	0.29
EPS (Diluted)	2.31	2.03	1.37	0.71	0.45	0.29
EPS Growth	26.94%	48.18%	92.96%	57.78%	55.17%	61.11%
Free Cash Flow	380.15	179.28	223.64	143.99	43.85	-26.2
Free Cash Flow Per Share	0.94	0.44	0.55	0.36	0.11	-0.07
Dividend Per Share	0.620	0.620	0.410	0.213	0.100	0.050
Dividend Growth	51.22%	51.22%	92.49%	113.00%	100.00%	100.00%
Gross Margin	92.85%	93.45%	93.33%	88.80%	88.78%	89.21%
Operating Margin	31.06%	33.02%	31.42%	23.58%	19.57%	15.98%
Profit Margin	28.11%	29.38%	26.45%	18.80%	16.00%	14.68%
Free Cash Flow Margin	11.38%	6.36%	10.65%	9.43%	3.87%	-3.30%
EBITDA	1,102	989.71	713.25	403.23	260.33	165.03
EBITDA Margin	32.98%	35.13%	33.96%	26.41%	22.99%	20.79%
D&A For EBITDA	63.89	59.38	53.37	43.17	38.69	38.17
EBIT	1,038	930.33	659.88	360.06	221.64	126.86
EBIT Margin	31.06%	33.02%	31.42%	23.58%	19.57%	15.98%
Effective Tax Rate	7.55%	11.11%	13.30%	19.36%	15.83%	16.18%
Revenue as Reported	3,342	2,817	2,100	1,527	1,132	793.93
Advertising Expenses	-	-	-	2.94	5.48	6.38

Source: S&P Global Market Intelligence. Standard template. Financial Sources.